Edith Jasny
Overview
Explore the profile of Edith Jasny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hellgren F, Cagigi A, Cerveira R, Ols S, Kern T, Lin A, et al.
Nat Commun
. 2023 Jul;
14(1):4080.
PMID: 37429868
No abstract available.
2.
Hellgren F, Cagigi A, Cerveira R, Ols S, Kern T, Lin A, et al.
Nat Commun
. 2023 Jun;
14(1):3713.
PMID: 37349310
Licensed rabies virus vaccines based on whole inactivated virus are effective in humans. However, there is a lack of detailed investigations of the elicited immune response, and whether responses can...
3.
Medina-Magues L, Muhe J, Jasny E, Medina-Magues E, Roth N, Lopera-Madrid J, et al.
NPJ Vaccines
. 2023 Mar;
8(1):31.
PMID: 36871059
Despite the success of the widely used attenuated yellow fever (YF) vaccine, its global supply remains a substantial barrier to implementing vaccination campaigns in endemic regions and combating emerging epidemics....
4.
Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira R, et al.
Mol Ther Methods Clin Dev
. 2022 Oct;
27:309-323.
PMID: 36217434
A third vaccine dose is often required to achieve potent, long-lasting immune responses. We investigated the effect of three 8-μg doses of CVnCoV, CureVac's severe acute respiratory syndrome coronavirus 2...
5.
Medina-Magues L, Gergen J, Jasny E, Petsch B, Lopera-Madrid J, Medina-Magues E, et al.
Vaccines (Basel)
. 2021 Dec;
9(12).
PMID: 34960211
Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link...
6.
Armbruster N, Jasny E, Petsch B
Vaccines (Basel)
. 2019 Oct;
7(4).
PMID: 31569785
There is a global need for effective and affordable rabies vaccines, which is unmet by current vaccines due to limitations in their production capacities, required administration schedules, storage requirements, and...
7.
Rauch S, Jasny E, Schmidt K, Petsch B
Front Immunol
. 2018 Oct;
9:1963.
PMID: 30283434
Ever since the development of the first vaccine more than 200 years ago, vaccinations have greatly decreased the burden of infectious diseases worldwide, famously leading to the eradication of small...
8.
Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, et al.
J Immunol
. 2017 Jan;
198(4):1595-1605.
PMID: 28077601
Among innovative adjuvants conferring a Th1-shift, RNAdjuvant is a promising candidate. This adjuvant consists of a 547-nt uncapped noncoding ssRNA containing polyU repeats that is stabilized by a cationic carrier...
9.
Edwards D, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, et al.
J Transl Med
. 2017 Jan;
15(1):1.
PMID: 28049494
Background: Prophylactic and therapeutic vaccines often depend upon a strong activation of the innate immune system to drive a potent adaptive immune response, often mediated by a strong adjuvant. For...
10.
Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.
Int J Cancer
. 2014 Dec;
137(2):372-84.
PMID: 25530186
Protein- and peptide-based tumor vaccines depend on strong adjuvants to induce potent immune responses. Here, we demonstrated that a recently developed novel adjuvant based on a non-coding, long-chain RNA molecule,...